CRISPR is a revolutionary gene-editing technology that the author believes will be transformative this century, with EDIT (Editas) positioned as a key player developing CRISPR-based treatments for genetic disorders and cancers. The company's strategy of targeting rare diseases and licensing IP could be highly profitable, though the post is incomplete and doesn't provide full investment thesis or risk analysis.